Financhill
Back

Ascendis Pharma AS Quote, Financials, Valuation and Earnings

Ascendis Pharma AS Price Quote

$153.97
+5.08 (+3.41%)
(Updated: September 19, 2024 at 12:15 PM ET)

Ascendis Pharma AS Key Stats

Sell
41
Ascendis Pharma AS (ASND) is a Sell

Day range:
$145.77 - $150.43
52-week range:
$85.29 - $161.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
24.60
P/B ratio:
0%

Volume:
826.7K
Avg. volume:
808.2K
1-year change:
45.91%
Market cap:
$8.5B
Revenue:
$288.8M
EPS:
$-9.35

How Much Does Ascendis Pharma AS Make?

Is Ascendis Pharma AS Growing As A Company?

  • What Is Ascendis Pharma AS's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.25%
  • What Is Ascendis Pharma AS's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Ascendis Pharma AS Stock Price Performance

What Is Ascendis Pharma AS 52-Week High & Low?

Ascendis Pharma AS Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ascendis Pharma AS?

  • How Much Debt Does Ascendis Pharma AS Have?
    Total long term debt quarterly is $721M
  • How Much Cash Does Ascendis Pharma AS Have?
    Cash and short term investments quarterly total is $277.3M
  • What Is Ascendis Pharma AS’s Book Value Per Share?
    Book value per share is -6.00

Is Ascendis Pharma AS Cash Flow Positive?

Data Unavailable

Ascendis Pharma AS Return On Invested Capital

  • Is Management Doing A Good Job?
    ASND return on invested capital is -109.54%
  • What Is Ascendis Pharma AS Return On Assets?
    ROA measures how assets are converting to revenues and is -60.1%
  • What Is ASND Return On Equity?
    ROE is a measure of profitability and is 0%

Ascendis Pharma AS Earnings Date & Stock Price

Ascendis Pharma AS Competitors

  • Who Are Ascendis Pharma AS's Competitors?
    Below is a list of companies who compete with Ascendis Pharma AS or are related in some way:
    • Adaptimmune Therapeutics PLC (ADAP)
    • Akari Therapeutics PLC (AKTX)
    • Evaxion Biotech AS (EVAX)
    • Novo Nordisk AS (NVO)
    • Trinity Biotech PLC (TRIB)

Ascendis Pharma AS Dividend Yield

Ascendis Pharma AS Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -35.44%
Revenue: -25% -57.72%

Analyst Recommendations

Buy Recommendations: 10
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 193.11
Upside from Last Price: 29.7%

Major Shareholders

  • How many ASND shares are owned by institutional investors?
    106.4M ASND shares are owned by institutional investors
  • How many ASND shares are owned by insiders?
    0 ASND shares are owned by insiders